Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 13NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5Lymphoid 3Myeloid 2Plasma cell 1Classical hematology 1CNS 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Dexamethasone 36Melphalan 29Cyclophosphamide 28Specimen Handling 26Biopsy 26Bortezomib 24Calcium Dobesilate 20Magnetic Resonance Spectroscopy 19Lenalidomide 17fludarabine phosphate 15Filgrastim 15Peripheral Blood Stem Cell Transplantation 13Vincristine 12Prednisone 12dexamethasone acetate 11dexamethasone 21-phosphate 11auricularum 11carfilzomib 10Doxorubicin 10sargramostim 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6ixazomib 6Rituximab 6Etoposide 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Transplantation × Plasma cell × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡